Ultralife (ULBI) Common Equity (2010 - 2026)

Ultralife has reported Common Equity for 17 years, with the latest figure at $129.6 million in Q1 2026.

• For the quarter ending Q1 2026, Common Equity fell 5.11% year-over-year to $129.6 million; the trailing twelve-month figure through Mar 2026 stood at $129.6 million (down 5.11% YoY), and the FY2025 full-year result was $130.1 million, down 3.02% from the prior year.
• Common Equity for Q1 2026 stood at $129.6 million, roughly flat from $130.1 million in the prior quarter.
• The five-year high for Common Equity was $138.6 million in Q2 2025, with the low at $115.2 million in Q3 2022.
• Average Common Equity over 5 years is $126.6 million, with a median of $128.9 million recorded in 2024.
• Year-over-year, Common Equity advanced 11.42% in 2024 and decreased 5.11% in 2026.
• Tracing ULBI's Common Equity over 5 years: stood at $116.3 million in 2022, then climbed by 7.87% to $125.4 million in 2023, then grew by 6.98% to $134.2 million in 2024, then dropped by 3.02% to $130.1 million in 2025, then fell by 0.39% to $129.6 million in 2026.
• The last three Common Equity figures came in at $129.6 million (Q1 2026), $130.1 million (Q4 2025), and $137.4 million (Q3 2025), per Business Quant data.

Peer Comparison